Pondimin Articles
Diet drug trial finishes first phase
30 May 2005
Wyeth wins further diet drug cases
18 April 2005
Wyeth wins PA diet drug trial
7 March 2005
Wyeth wins one of two PA diet drug cases
10 January 2005
Wyeth wins multiple Philadelpha diet drug cases
23 August 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Wyth sees 3rd-quarter loss on charges
27 October 2003
European court overturns obesity drug ban
3 February 2003
AHP changes name to Wyeth
18 March 2002
AHP overcomes fen-phen problems to post strong growth for 2001
4 February 2002
AHP takes $950 mill fen-phen charge
24 October 2001
AHP and Interneuron bury diet drug hachet
1 June 2001
AHP takes $7.5 billion charge for fen-phen
26 January 2001
AHP reaping benefits of R&D spend
20 October 2000
AHP posts healthy 2nd quarter results
24 July 2000
AHP posts 18% net income growth
20 April 2000
AHP going ahead with fen-phen settlement
17 April 2000
Antiobesity drugs to be banned in EU
6 April 2000
Antiobesity drugs to be banned in EU
31 March 2000
Interneuron sues AHP over "fen-phen" data
27 January 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
AHP diet drug settlement approved
25 November 1999
Xenical, Meridia drive US antiobesity drugmarket
15 November 1999
American Home Products confirms merger talks with Warner-Lambert
3 November 1999
AHP settling fen-phen cases in California
11 October 1999
BASF Pharma hoping to catch up with top pharmaceutical companies
23 September 1999
AHP close to settling $3 billion lawsuits?
17 September 1999
Stock Commentary New York
12 August 1999
Stock Commentary New York
22 July 1999
Charges against AHP executives dismissed
22 February 1999
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
US FDA Proposed Rule On Banned Drugs
13 October 1998
Phentermine To Blame for Fen-Phen Side Effects?
1 September 1998
Wyeth Withdraws Duract Due To Serious Liver Events
24 June 1998
US Quarterly Financial Results Round-Up
23 April 1998
Redux Study Casts Doubt On Valve Disease Problem
1 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
"No Comment" On SB/AHP Tie-Up Rumors
19 January 1998
Stock Commentary New York
7 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Wyeth-Ayerst Recalls Redux And Pondimin
17 September 1997
Wyeth To Begin Redux Neurotoxicity Study
4 September 1997
Obesity Drug Sales Show Strong Rise In January
24 March 1997
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Strong Growth At AHP At Start Of 1996
6 May 1996
INTERNEURON DEFENDS DEXFENFLURAMINE
16 May 1994
Showing 1-58 of 58 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
